Regeneron Pharmaceuticals, Inc. (REGN) reported additional positive results from a phase 3 trial, which assessed use of a single dose of investigational REGEN-COV to prevent COVID-19. REGEN-COV reduced the risk of contracting COVID-19 by 81.6% during the pre-specified follow-up period of months 2-8, maintaining the 81.4% risk reduction during the first month after administration previously reported.
"In this trial, a single dose of REGEN-COV provided long-term protection against COVID-19, including times of particularly high risk from household exposure, and in the longer-term during ongoing broader exposure," said George Yancopoulos, President and Chief Scientific Officer at Regeneron.
For comments and feedback: editorial@rttnews.com